

INDEX

- adCSNB (autosomal dominant congenital stationary night blindness)
 ERG findings in two patients with, 377–384
 mutations in gene encoding β PDE, 313–322
- ADRP (autosomal dominant retinitis pigmentosa)
 see retinitis pigmentosa
- Albino rat
 Fischer 87–94
 Lewis, 106
 Wistar, 88–94
- Apoptosis
 in retinitis pigmentosa, 1–8
 in transgenic mice, 39–49
 inhibitory effects of cycloheximide and flunarizine on light-induced apoptosis of photoreceptor cells, 27–38
 light-induced apoptosis in the rat retina in vivo, 19–25
- Argon laser photocoagulation, retinal cell responses to, 209–215
 blood-retinal-barrier breakdown, 212–213, 216
 phagocytic cells, 213–218
- ARRP (autosomal recessive retinitis pigmentosa)
 see retinitis pigmentosa
- BALB/c, 168–171
- Bardet-Biedl syndrome, 298
- Batten disease, 79
- Best disease, 327
- Bruch's membrane, 87–94, 279
- C3H/Hen, 163–175
- Calcium, 119–129, 227–233
- Campbell, 179–184
- Chick, dolichol pathway in the RPE, 149–153
- Chinchilla, 187
- Choriocapillaris, in RP, 279
- Cones
 abnormal cone receptor activity in patients with hereditary degeneration, 349–358
 in RP, 275–277
 L/M cone opsin, 195–201
- Cones (*cont.*)
 macaca monkey 195–201
- Cycloheximide, inhibitory effects of, 27–38
- DHA (docosahexaenoic acid)
 abnormalities in RBC of patients with RP, 385–393
 x-linked RP, 385–391
- DMTU (dimethylthiourea), 9
- Drosophila
 abnormal Ca^{2+} mobilization and excessive photopigment phosphorylation lead to photoreceptor degeneration in, 227–234
 model for photoreceptor dystrophies and cell death, 217–226
 ninaA, 270
 ninaE, 218–219, 235–241
 norpA, 264–269
 photoreceptor proteins, 263–274
 rdg gene, 218
 role of retinal degeneration B protein in, 243–254
 role of dominant rhodopsin mutation in, 235–241
 visual transduction, a model system for human eye disease, 255–261
- EAU (experimental autoimmune uveoretinitis), 105–110
- EGF (epidermal growth factor), 69–76
- ERG (electroretinogram)
 adCSNB, 377–384
 in drosophila, 246–247
 cone ERG delayed, 356–357
- Fischer, 87–94
- Flunarizine, inhibitory effects of, 27–38
- GAR1 gene, 331–338
- GCAP (guanylate cyclase-activating protein), 339–347

Genetics

- ADRP, clinical features of, 303–312
- ARRP
 - Bardet-Biedl syndrome, 298
 - chromosome 14, 296
 - in Sardinian population, 295
 - mutation of the β PDE gene, 315–318
- ASN244Lys, 288
- ASN244His, 288
- GCAP, 339–347
- HPV16E7, 39–49
- molecular analysis of the human GAR1 gene, 331–338
- P53, 39–49
- peripherin/RDS, 285–292
- Green light experiment, 220–223
- Growth factors
 - effects on nitric oxide, 62–63, 66
 - EGF, 69–76
- HPLC (high pH anion exchange chromatography), 150–151
- IgG, 214
- IRBP(interphotoreceptor retinoid binding protein), 159–160, 278–279, 395–402
- Iron involvement in retinal degeneration, 177–186
- Lewis, 106
- Long Evans, 165
- Macular Degeneration
 - Arg172Trp, 290
 - Arg172Gln, 290
 - genetic studies of, 323–330
 - dominant cystoid macular dystrophy, 327
 - north carolina macular dystrophy, 327
 - sorsby's fundus dystrophy, 325, 327
 - TIMP3 mutation, 324–325
- MDCK (Madin-Darby canine kidney), 151
- MMPs (matrix metalloproteinases), 95–96
- mdn (motor neuron degeneration), 79
- Monkey, development of opsin and synapses of photoreceptors in, 195–202
- Mouse
 - C3H/Hen, 163–175
 - mdn, 79
 - nr, 78
 - pcd, 78
 - rds, 40
 - rd1, 40, 78, 168
 - Rd2, 78
 - rd3, 80
 - Rd4, 80–81
 - rd5, 81
 - transgenic
 - IRBP-SV40 TAq, 41–42
 - IRBP-E7, 42–48
 - viteligo, 155–162

Müller cells

- argon laser photocoagulation, 210, 214–215
- in RP, 280–281
- Naphthalene, induced retinal degeneration in rabbit, 203–208
- New Zealand, 187
- NHI (nonhaem iron), 177–186
- ninaA, preliminary identification and characterization, 270
- ninaE
 - identification and characterization of, 237–238
 - retinal dystrophy models, 218–219
 - rhabdomeres, 236–237
- NorPA
 - identification and characterization of, 265–266
 - phototransduction, 264
- NCMD (North Carolina macular dystrophy), 237
- nr, 78
- Opsin
 - effects of visible light, 13–16
 - L/M cone opsin, 195–201
- pcd, 78
- PEDF (pigment epithelium-derived factor), function, age-related expression and molecular characterization of, 51–60
- Peripherin/RDS, autosomal dominant retinal degeneration, 285–292
- Photoreceptor
 - photoreceptors degeneration in drosophila, 227–234
 - abnormal rod photoreceptor function in RP, 359–370
 - drosophila as a model for, 217–226
 - effect of sugars on, 129–137
 - guanylate cyclase-activating protein in vertebrate photoreceptors, 339–347
 - in vitiligo mouse, morphological and electrophysiological characterization of, 156–157
 - morphology, 188
 - normal death of, 192
- Phototransduction, in vertebrate and invertebrate, 263–265
- Rabbit
 - chinchilla, 187
 - naphthalene-induced retinal degeneration in, 203–208
 - New Zealand, 187
- Rat
 - Campbell, 179–184
 - Fischer, 87–94
 - Lewis, 106
 - Long Evans, 165
 - RCS, 40, 119–126, 129, 171–173, 187, 191, 209–215, 257

- Rat (*cont.*)
 RCS-rdy⁺, 112
 rdy, 40, 187
 Wistar, 88–94, 178–183
 RCS, 40, 119–126, 129, 171–173, 187, 191, 209–215, 257
 RCS-rdy⁺, 112
 rd1, 40, 78, 168
 Rd2, 78
 rd3, 80
 Rd4, 80–81
 rd5, 81
 rds, 40
 rdy, 40, 187
 Retina
 nitric oxide in, 61–68
 response to argon laser photocoagulation, 209–216
 Retinal degeneration
 apoptosis of photoreceptors and lens fiber cells with cataract, 39–49
 drosophila
 model for photoreceptor dystrophies and cell death, 217–226
 visual transduction, a model system for human eye disease, 255–261
 GCAP candidate gene for human disease, 345
 fractionation of interphotoreceptor MMPs, 95–103
 hereditary degeneration of the retina, 177–186
 inhibition of calcium mobilization, 229–231
 in mouse, 77–85
 in vitiligo mouse, 155–162
 light-induced apoptosis in the rat retina *in vivo*, 19–25
 molecular analysis of the human GARI gene, 331–338
 mutations in the gene for the
 β-subunit of rod photoreceptor cGMP-specific PDEβ in patients with, 313–322
 newly formed capillaries in experimental naphthalene-induced retinal degeneration in rabbit, 203–208
 nitric oxide, 61–68
 oxidative damage and responses in retinal nuclei arising from intense light exposure, 9–17
 effects of visible light on the opsin gene, 13
 retinal damage as assessed by rhodopsin loss, 12
 role of dominant rhodopsin mutations in, 235–241
 vitamin E deficiency, 111–118
 Retinal development, receptor degeneration is a normal part of, 187–193
 DNA fragmentation, 188–190
 morphological differentiation of photoreceptors, 188
 Retinal transplantation, immunological aspects of, 163–175
 Retinitis Pigmentosa
 abnormal cone receptor activity in patients with hereditary degeneration, 349–358
 abnormal rod photoreceptor function in, 359–370
 ADRP
 clinical features of, 303–312
 DHA, 385–393
 peripherin/RDS gene, 285–292
 apoptosis, 1–8
 argon laser photocoagulation, 209
 ARRP, genetic studies in, 293–302
 cataractogenesis in, 403–407
 DHA abnormalities in RBC of patients with, 385–393
 retinal pathology in, 275–284
 X-linked recessive RP, 371–376, 385–391
 Retinoid metabolism, 157–159
 Rhodopsin
 clinical features of ADRP associated with Ser186Trp mutation of, 303–312
 regulatory influences on the glycosylation of rhodopsin by human and bovine retinas, 139–146
 role of dominant rhodopsin mutations in drosophila retinal degeneration, 235–241
 Thr17met mutation, 40
 Rods
 abnormal rod photoreceptor function in RP in RP, 275–277
 macaca monkey, 195
 RPE (retinal pigment epithelium)
 characterization of PEDF by human RPE cells, 51–60
 dolichol pathway in the RPE of the embryonic chick, 149–153
 from RCS rats, 119–129
 functional studies of, 156–157
 grafts, 172–174
 in RP retina, 279
 in vitiligo mouse, morphological and electrophysiological characterization of, 155–156
in vitro expression of epidermal growth factor receptor by human RPE cells, 69–76
 SFD (Sorby's fundus dystrophy), 325–327
 SMD (senile macular degeneration), 87–94
 Stargardt's macular dystrophy, 327
 Sugar
 effect on photoreceptor outer segment assembly, 129–137
 regulatory influences on the glycosylation of rhodopsin by human and bovine retinas, 139–146
 Transgenic mouse, expression of S opsin, 201
 Tunnel, 29, 32–35, 41, 188–192,
 Usher's syndrome, 385

- Virus
- cytomegalovirus, 64
 - human papilloma virus 16 (HPV16) E7, 39–49
- Visual cycle, 157–158
- Vitamin A, 159, 161
- Vitamin E, deficiency, 111–118
- Vitiligo mouse, 155–162
- Wistar, 88–94, 178–183
- X-linked RP, 371–376, 385–391
- Xenopus laevis, 129–131, 134–136
- Zebrafish, 200